Joseph Keenan

Joseph Keenan's Title

Joseph Keenan is a seasoned reporter who has carved out a niche in covering significant developments in the pharmaceutical and healthcare sectors. His investigative prowess and keen attention to detail have made him a respected voice in the industry. His role often involves breaking down complex scientific developments and regulatory actions into plain language that is accessible to the general public, thereby contributing to informed public discourse on these critical issues.

Joseph Keenan's Coverage of Emergent BioSolutions

Joseph Keenan reported on Emergent BioSolutions being awarded a substantial $235.8 million contract to supply the anthrax vaccine BioThrax to the U.S. Department of Defense. This contract underscores the importance of BioThrax in national defense and highlights Emergent BioSolutions' pivotal role in public health preparedness. Keenan's reporting on this contract provides valuable insights into government procurement practices and the ongoing efforts to safeguard military personnel against biological threats.

Joseph Keenan's Reporting on FDA Actions

Joseph Keenan has extensively covered various actions by the U.S. Food and Drug Administration (FDA) that impact the pharmaceutical industry. For instance, he reported on FDA Commissioner Robert Califf's call for more plain-language scientific evidence to combat vaccine misinformation, highlighting the agency's commitment to public health. Additionally, Keenan covered the FDA's warning letter to Chinese API maker Sichuan Deebio for significant deviations in manufacturing operations and the issuance of a Complete Response Letter (CRL) to Zealand Pharma for its hypoglycemia drug due to manufacturing problems. These reports underscore the FDA's rigorous regulatory standards and its role in ensuring drug safety and efficacy.

Joseph Keenan's Coverage of Vaccine Manufacturing

Joseph Keenan has been at the forefront of reporting on the challenges and developments in vaccine manufacturing. His coverage includes Moderna's consideration to scale back COVID-19 vaccine manufacturing in response to falling demand, reflecting the dynamic nature of vaccine production amidst changing pandemic conditions. Additionally, he reported on Japan awarding $115 million to an Arcturus Therapeutics joint venture to boost mRNA vaccine manufacturing, showcasing global efforts to enhance vaccine production capabilities. Keenan's reports provide a comprehensive view of the strategic decisions and investments shaping the future of vaccine availability.

Joseph Keenan's Reporting on Public Health Campaigns

In his coverage of public health initiatives, Joseph Keenan reported on the CDC's 'Wild to Mild' campaign aimed at reversing the decline in flu vaccine use among key demographic groups. This campaign is a critical response to ensure widespread flu vaccination, particularly in the wake of the COVID-19 pandemic. Keenan's insights into this campaign highlight the CDC's strategies to improve public health outcomes through targeted communication and outreach efforts. His reporting underscores the importance of vaccination campaigns in maintaining public health and preventing disease outbreaks.